Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
Analyst Ratings
This is a breakdown of current ratings and target prices for Alaunos Therapeutics and Kiniksa Pharmaceuticals International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alaunos Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Kiniksa Pharmaceuticals International | 0 | 2 | 8 | 0 | 2.80 |
Kiniksa Pharmaceuticals International has a consensus price target of $87.38, suggesting a potential upside of 12.15%. Given Kiniksa Pharmaceuticals International’s stronger consensus rating and higher possible upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Alaunos Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Alaunos Therapeutics | N/A | -232.60% | -158.99% |
| Kiniksa Pharmaceuticals International | 9.59% | 13.65% | 10.09% |
Risk and Volatility
Alaunos Therapeutics has a beta of -0.97, meaning that its share price is 197% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.
Valuation & Earnings
This table compares Alaunos Therapeutics and Kiniksa Pharmaceuticals International”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alaunos Therapeutics | $3,000.00 | 1,392.77 | -$4.18 million | ($1.91) | -0.86 |
| Kiniksa Pharmaceuticals International | $677.56 million | 8.97 | $59.01 million | $0.97 | 80.32 |
Kiniksa Pharmaceuticals International has higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 53.9% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Kiniksa Pharmaceuticals International beats Alaunos Therapeutics on 13 of the 14 factors compared between the two stocks.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
